Sunshine Biopharma (SBFM) Gross Profit (2018 - 2026)

Sunshine Biopharma has reported Gross Profit for 9 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit fell 20.12% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $11.7 million (up 5.98% YoY), and the FY2025 full-year result was $12.3 million, up 14.86% from the prior year.
• Gross Profit for Q1 2026 stood at $2.2 million, down from $3.0 million in the prior quarter.
• The five-year high for Gross Profit was $3.4 million in Q2 2025, with the low at $62800.0 in Q1 2022.
• Historically, Gross Profit has averaged $2.1 million across 5 years, with a median of $2.4 million in 2024.
• Annual changes were most pronounced in 2022 — Gross Profit jumped 6157.61% — and 2026, when it decreased 20.12%.
• Sunshine Biopharma's Gross Profit stood at $1.5 million in 2022, then jumped by 72.22% to $2.6 million in 2023, then increased by 20.44% to $3.1 million in 2024, then decreased by 2.08% to $3.0 million in 2025, then fell by 27.99% to $2.2 million in 2026.
• The last three Gross Profit figures came in at $2.2 million (Q1 2026), $3.0 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.